- Home
- Â /Â GeneDx Holdings
GeneDx Holdings
Stock Price
$84
2024-10-29
Market Capitalization
$2.3 B
2024-10-29
Revenue
$202.6 M
FY, 2023
GeneDx Holdings Summary
Company Summary
- Overview
- GeneDX Holdings (formerly Sema4 Holdings) is a health information company applying AI and machine learning to clinical and genomic data. It develops Centrellis, a health intelligence platform for health data management and analytics. In addition, the company offers women’s health, hereditary cancer, biopharma, research, and testing solutions.
- Type
- Public
- Status
- Active
- Founded
- 2020
- HQ
- Stamford, CT, US | view all locations
- Website
- https://ir.genedx.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Kevin Feeley, Chief Financial Officer
Alan B. Copperman, Chief Medical Officer
Paul Kruszka, Chief Medical Officer
Operating MetricsView all
Tests Performed Yearly (NGS)
250K
Q3, 2021
Data Managed per Month, petabytes
46
FY, 2021
De-identified Clinica Records in Database
12M
FY, 2021
GeneDx Holdings Financials
Summary Financials
- Revenue (Q3, 2024)
- $76.9M
- Gross profit (Q3, 2024)
- $47.8M
- Net income (Q3, 2024)
- ($8.3M)
- Cash (Q3, 2024)
- $57.9M
- EBIT (Q3, 2024)
- ($7.8M)
- Enterprise value
- $2.3B